Peculiarities of the correction of hormonal and metabolic risk factors in patients with ischemic heart disease

Abstract

IL‑1β by 7.4 % (p=0.021), IL‑6 by 6.1 % (р=0.011), and IL‑8 by 12.3 % (р=0.18); the level of HDL CS increased by 7.9 % (р=0.02). In the SDT+D group, levels of TG decreased by 26.3 % (p<0.001), oxLDL by 14.4 % (р<0.001), insulin by 22.4 % (p<0.001), ACTH by 20.4 % ( p<0.001), cortisol by 23.9 % ( p<0.001), IL ‑ 1β by 52.1 % ( p<0.001), IL ‑ 6 by 56.3 % ( p<0.001), IL ‑ 8 by 60.2 % (p<0.001), the HOMA‑IR score by 38.8 % (p<0.001), and the depression score by 26.9 % (p<0.001); levels of HDL CS and β‑endorphin increased by 17.4 % and 32.6 %, respectively (p<0.001 for both). Conclusion. Using dalargin in the treatment of IHD patients with MS enhances the efficacy of correcting hypertriglyceridemia, HDL CS deficiency, insulin resistance, hypercortisolemia, proinflammatory cytokine activity, and depression. These effects may be due to activation of the opioidergic neuropeptide system possessing a stress ‑limiting capacity.